Pathological aspects of diabetic angiopathy;Aspects physiopathologiques de l'angiopathie diabetique

Diabetes and Metabolism

Volumn 25, Issue SUPPL. 3, 1999, Pages 21-26

  Wautier, J L ^a   Wautier, M P ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b INSERM   (France)

Author keywords

Atherosclerosis; Diabetes; Glycoxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETIC ANGIOPATHY; DRUG MECHANISM; GENETIC MANIPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION;

ANIMALS; BLOOD PROTEINS; DIABETIC ANGIOPATHIES; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; RECEPTORS, CELL SURFACE; RISK FACTORS;

EID: 0033066950     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. King GI, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus Ann Rev Med, 1994, 45, 179-188.
2. Brownlee M. Advanced glycation end products in diabetic complications. Curr Opin Endocrinol Diabetes, 1996, 3, 291-297.
3. Maillard LC. Action des acides aminés sur les sucres. Formation des mélanoïdes par voie méthodique. CR Acad Sci (France), 1952, 154, 66-68.
4. Wautier JL. Les produits de glycation avancée ou produits de Maillard. Rev Prat, 1998, 1865-1867.
5. Steinbrecher U, Witztum JL. Glycosylation of low-density lipoproteins on a extent comparable to that seen in diabetes shows their catabolism. Diabetes, 1984, 33, 130-134.
6. Vlassara H, Brownlee M, Cerami A. high-affinity receptor-mediated uptake and degradation of glucose-modified proteins : a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA, 1985, 82, 5588-5592.
7. Bucala R, Makita Z, Koscjinsky T, Cerami A, Vlassara H. Lipid advanced glycation pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA, 1993, 90, 6434-3438.
8. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Europ J. Clin Invest, 1997, 27, 97-108.
9. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb, 1994, 14, 1521-1528.
10. Neeper M, Schmidt AM, Brett, J, et al. Cloning expression of RAGE : a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem, 1992, 267, 14998-15004.
11. Wautier JL, Paton CR, Wautier MP, et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and their relation to the vascular complications. N Engl J Med, 1981, 305, 237-242.
12. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGE) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature : a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA, 1994, 91, 7742-7746.
13. Wautier JL, Guillausseau PJ. Diabetes, advanced glycation end products and vascular disease. Vascular Medicine, 1998, 3, 131-137.
14. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997, 40, 238-243.
15. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthal, 1994, 112, 1217-1228.
16. Guillausseau PJ, Massin P, Charles MA, et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus : a longitudinal study. Diabetic Med, 1998, 15, .151-155.
17. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int, 1995, 47, 1703-1720.
18. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med, 1991, 325, 836-842.
19. Zidayeh FN, Cohen MP. Effects of glycated albumin on mesangial cells : evidence for a role in diabetic nephropathy. Mol Cell Biochem, 1993, 125, 19-25.
20. Kannel WB, Mc Gee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease the Framingham Study. Diabetes Care, 1979, 2, 120-126.
21. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol, 1995, 75, 894-903.
22. Uusitupa MIJ, Niskanen LK, Sütonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non diabetic subjects. Diabetologia, 1993, 36, 1175-1184.
23. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes, 1994, 43, 960-967.
24. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J, 1996, 17, 1337-1344.
25. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol, 1993, 143, 1649-1656.
26. Sims TJ, Rasmussen LM, Oklund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996, 39, 946-51.
27. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relations between complications to type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med, 1986, 314, 403-408.
28. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest, 1991, 87, 432-438.
29. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 323, 1629-1632.
30. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hypermeability in diabetic rats. J Clin Invest, 1996, 97, 238-243.
31. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of RAGE : a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis (in press).
32. Renard C, Chappey O Wautier MP, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol, 1997, 52, 54-62.